Eli Lilly today announced plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States. This brings the company’s total U.S. capital expansion commitments to more than $50 billion since 2020.
Three of the future U.S. sites announced today will focus on manufacturing active pharmaceutical ingredients (API), reshoring critical capabilities of small molecule chemical synthesis and further strengthening Lilly’s supply chain. The fourth location will extend the company’s global parenteral manufacturing network for future injectable therapies.
At these four new sites, Lilly expects to create more than 3,000 jobs for highly skilled workers, including engineers, scientists, operations personnel and lab technicians. Additionally, the company anticipates that it could create nearly 10,000 construction jobs during the development of the sites.
Expected additional economic benefits of these new sites to the selected communities include increased local spending, tax revenue, economic diversification, improved infrastructure, population growth, and training and development opportunities.
The company’s previous total domestic capital expansion commitments from 2020 to 2024 totaled $23 billion and represented in today’s $50 billion announcement, included:
- New sites in Research Triangle Park and Concord, North Carolina
- New sites at the LEAP Innovation District in Lebanon, Indiana
- Expansions and updates to several different manufacturing facilities in Indianapolis
- Development of the new Lilly Medicine Foundry in Lebanon, Indiana
- Acquisition and expansion of Lilly’s manufacturing site in Kenosha County, Wisconsin